STOCK TITAN

Oruka Therapeutics general counsel sells 9,000 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. General Counsel Paul T. Quinlan exercised employee warrants for 9,000 common shares at $7.8000 per share on November 20, 2026, then sold 9,000 common shares that day: 3,300 at a weighted-average $94.0485, 3,000 at $94.7732, 2,500 at $95.9944 and 200 at $96.6000 per share. The sales were effected under a Rule 10b5-1 trading plan entered into May 15, 2026.

Insider Quinlan Paul T
Role General Counsel
Sold 9,000 shs ($854K)
Approx. gross sale proceeds $854K
Approx. exercise cost $70K
Approx. pre-tax spread $784K
Share of Position Sold 23.1%
Type Security Shares Price Value
Exercise Employee Warrant (right to buy) F6 9,000 $0.00 $0.00
Exercise Common Stock 9,000 $7.80 $70K
Sale Common Stock F1, F2 3,300 $94.0485 $310K
Sale Common Stock F1, F3 3,000 $94.7732 $284K
Sale Common Stock F1, F4 2,500 $95.9944 $240K
Sale Common Stock F1, F5 200 $96.60 $19K
Holdings After Transaction: Employee Warrant (right to buy) — 61,996 warrants (Direct); Common Stock — 29,995 shares (Direct)
Holdings Before and After: Employee Warrant (right to buy), 70,996 to 61,996 warrants (Direct); Common Stock, 29,995 to 29,995 shares (Direct)
Other Insiders: 4 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (6)
  1. F1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.
  2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.40 to $94.38, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.
  3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.46 to $95.22, inclusive.
  4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.52 to $96.30, inclusive.
  5. F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.56 to $96.64, inclusive.
  6. F6. The warrant vests as to 1/4 of the underlying shares on April 30, 2025 and as to 1/48 of the underlying shares monthly from April 30, 2025.
Employee warrant shares exercised 9,000 shares November 20, 2026
Exercise price $7.8000 per share Employee warrant exercise on November 20, 2026
Common shares sold 9,000 shares November 20, 2026, under a Rule 10b5-1 trading plan
Weighted-average sale price for 3,300 shares $94.0485 per share November 20, 2026
Weighted-average sale price for 3,000 shares $94.7732 per share November 20, 2026
Weighted-average sale price for 2,500 shares $95.9944 per share November 20, 2026
Weighted-average sale price for 200 shares $96.6000 per share November 20, 2026
Reported employee-warrant position after exercise 61,996 shares Following the November 20, 2026 exercise
Rule 10b5-1 trading plan regulatory
"sales were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Employee Warrant (right to buy) technical
"Employee Warrant (right to buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ORKA shares did Paul T. Quinlan sell on November 20, 2026?

He sold 9,000 shares in four transactions: 3,300 at a weighted-average $94.0485, 3,000 at $94.7732, 2,500 at $95.9944 and 200 at $96.6000 per share. The sales were effected under a Rule 10b5-1 trading plan entered into May 15, 2026.

What happened to Paul T. Quinlan's ORKA employee warrants?

He exercised 9,000 employee warrants at $7.8000 per share on November 20, 2026. His reported warrant position after the exercise was 61,996 shares, and the warrant's stated expiration date is July 14, 2034.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Quinlan Paul T

(Last)(First)(Middle)
C/O ORUKA THERAPEUTICS, INC.
855 OAK GROVE AVE., SUITE 100

(Street)
MENLO PARK CALIFORNIA 94025

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
General Counsel
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/20/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/20/2026M9,000A$7.838,995D
Common Stock11/20/2026S(1)3,300D$94.0485(2)35,695D
Common Stock11/20/2026S(1)3,000D$94.7732(3)32,695D
Common Stock11/20/2026S(1)2,500D$95.9944(4)30,195D
Common Stock11/20/2026S(1)200D$96.6(5)29,995D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Warrant (right to buy)$7.811/20/2026M9,000 (6)07/14/2034Common Stock9,000$061,996D
Explanation of Responses:
1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.40 to $94.38, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.46 to $95.22, inclusive.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.52 to $96.30, inclusive.
5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.56 to $96.64, inclusive.
6. The warrant vests as to 1/4 of the underlying shares on April 30, 2025 and as to 1/48 of the underlying shares monthly from April 30, 2025.
/s/ Paul Quinlan11/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading